Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Heron Therapeutics (HRTX) Income towards Parent Company: 2009-2024

Historic Income towards Parent Company for Heron Therapeutics (HRTX) over the last 16 years, with Dec 2024 value amounting to -$14.0 million.

  • Heron Therapeutics' Income towards Parent Company rose 8.19% to -$4.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 106.16%. This contributed to the annual value of -$14.0 million for FY2024, which is 87.39% up from last year.
  • Per Heron Therapeutics' latest filing, its Income towards Parent Company stood at -$14.0 million for FY2024, which was up 87.39% from -$111.1 million recorded in FY2023.
  • In the past 5 years, Heron Therapeutics' Income towards Parent Company ranged from a high of -$14.0 million in FY2024 and a low of -$226.4 million during FY2020.
  • Over the past 3 years, Heron Therapeutics' median Income towards Parent Company value was -$111.1 million (recorded in 2023), while the average stood at -$100.2 million.
  • As far as peak fluctuations go, Heron Therapeutics' Income towards Parent Company declined by 10.50% in 2020, and later spiked by 87.39% in 2024.
  • Heron Therapeutics' Income towards Parent Company (Yearly) stood at -$226.4 million in 2020, then increased by 2.93% to -$219.8 million in 2021, then climbed by 20.16% to -$175.5 million in 2022, then soared by 36.68% to -$111.1 million in 2023, then spiked by 87.39% to -$14.0 million in 2024.